Basic Remeron Information

• INN (International Nonproprietary Name): Mirtazapine.
• Brand Names Available In Australia: Avanza is listed for Australia, with Remeron and Remeron SolTab appearing in international packaging references.
• ATC Code: N06AX11.
• Forms & Dosages: Film-coated tablets 7.5 mg, 15 mg, 30 mg and 45 mg; orally disintegrating tablets (ODT) 15 mg, 30 mg and 45 mg.
• Manufacturers In Australia: Originator is Organon (Merck & Co. group) and multiple generics are supplied internationally by manufacturers such as Teva, Sandoz, Accord Healthcare, Egis and Sun Pharma; local manufacturer names vary.
• Registration Status In Australia: not specified.
• OTC / Rx Classification: Prescription-only medicine (Rx) in major markets.
• Typical Adult Dosage Summary: Initial 15 mg once daily in the evening, usual range 15–45 mg/day, maximum 45 mg/day.
• Storage & Transport: Store at room temperature (20–25 °C) and protect from moisture and light; keep ODTs in original blister until use.
• Absolute Contraindications: Hypersensitivity to mirtazapine or excipients and concurrent or recent MAOI use (within 14 days).

Latest Research Highlights (Australia + Global, 2022–2025)

Clinicians ask whether mirtazapine still has a place in modern antidepressant practice.

Recent Australian and international trials from 2022–2025 continue to show that mirtazapine is effective for major depressive disorder, with a distinctive early sedative effect helpful for sleep symptoms.

Comparative moderate‑severity cohorts report comparable remission rates to some SSRIs while showing faster early improvements in insomnia and sleep quality in the first weeks of treatment.

Australian pharmacoepidemiology and TGA adverse‑event surveillance from 2022–2024 flagged increased weight and somnolence as the leading harms reported.

Rare events recorded in surveillance included blood dyscrasias and mild elevations in hepatic enzymes, consistent with international safety profiles.

International meta‑analyses published in 2023–2024 suggest mirtazapine may outperform SSRIs for depression with comorbid insomnia or marked anorexia and is commonly used off‑label to stimulate appetite in palliative care.

Comparative safety summaries favour mirtazapine for a lower rate of sexual dysfunction relative to SSRIs, but a higher risk of weight gain and early sedation.

Evidence gaps remain around long‑term metabolic outcomes and adolescent use; several 2024 Australian observational datasets recommended establishment of TGA‑funded registries to track metabolic sequelae.

Clinical Effectiveness In Australia (PBS & TGA Insights)

Many prescribers in Australia choose mirtazapine when sedation or appetite gain would be clinically helpful.

PBS listings and prescribing patterns show primary use for major depressive disorder, often after SSRI intolerance or insufficient response.

TGA adverse‑event monitoring emphasises early sedation and weight gain as common concerns reported by prescribers and pharmacists.

Local audits indicate clinicians adopt slower uptitration in older patients and more frequent dose reductions in rural clinics because of higher comorbidity loads.

Organon originator products and multiple generics supply Australian pharmacies, with film‑coated tablets and ODT options used depending on patient needs.

Clinical audits from Australian mental health services (2022–2024) reported improved sleep metrics and appetite in palliative and geriatric cohorts started on mirtazapine.

Indications & Expanded Uses (TGA‑Approved And Off‑Label)

Which conditions commonly lead to a mirtazapine prescription?

• Approved Indications: Major depressive disorder (aligns with international approvals).
• Off‑Label Uses: Short‑term insomnia management, appetite stimulation in cachexia and adjunctive treatment where sedation is desirable.
• Special Considerations: Use in bipolar disorder requires caution because of manic switch risk and should involve specialist oversight.

Use in children and adolescents is not routinely recommended and requires specialist case‑by‑case consultation.

In palliative and oncology care, clinicians often prefer mirtazapine for combined antidepressant, appetite‑stimulating and antiemetic benefits.

Regulatory Status: Prescription only in Australia and other major markets; treatment duration recommendations commonly advise an acute phase of at least six months.

Decision Flow For Clinicians:

• Assess primary symptoms: depression with insomnia or anorexia → consider mirtazapine.
• Prior SSRI intolerance or sexual dysfunction concerns → consider switching to or initiating mirtazapine.
• Bipolar disorder or adolescent patient → consult specialist before prescribing.

Composition & Brand Landscape

Mirtazapine is the active ingredient, listed as the INN.

Originator products come from Organon (Merck & Co. group), with generics supplied by manufacturers such as Teva, Sandoz, Accord Healthcare, Egis and Sun Pharma.

Australian brand names include Avanza, and international brands include Remeron and Remeron SolTab ODT presentations.

Available formulations sold include film‑coated tablets in strengths 7.5 mg, 15 mg, 30 mg and 45 mg, and ODTs in 15 mg, 30 mg and 45 mg.

ATC classification is N06AX11, placing mirtazapine among other antidepressants in the N nervous system group.

Packaging And Storage Notes: ODTs must remain in original blister packaging to protect from moisture and should be dispensed with storage counselling for telehealth and postal fulfilment.

• Originator: Organon (Merck group).
• Generic: Typically chemically identical active ingredient manufactured by other companies and dispensed per PBS interchange rules.

Contraindications & Special Precautions

What to check before starting mirtazapine.

• Absolute Contraindications: Known hypersensitivity to mirtazapine or excipients, and concurrent or recent MAOI use (within 14 days).
• Special Precautions: Severe hepatic or renal impairment, cardiac conduction disorders, history of seizures, and bipolar disorder where manic switch is possible.
• Pregnancy And Breastfeeding: Require specialist risk–benefit discussion before prescribing.
• Indigenous And Remote Communities: Provide culturally safe informed consent and plan close follow‑up.

Daily Life Advice: Avoid driving or operating heavy machinery until sedation settles, and minimise alcohol due to additive sedative effects.

Dosage Guidelines

Patients often ask how to start and titrate mirtazapine safely.

Typical adult initiation is 15 mg once daily in the evening with titration across 15–45 mg per day, and a maximum of 45 mg daily.

Elderly patients should start at lower doses, often 7.5–15 mg, and escalate more slowly because of increased sensitivity.

Liver impairment requires dose reduction and monitoring, and severe renal impairment may require a reduced dose.

Children and adolescents are not routinely recommended for treatment without specialist consultation.

Treatment Duration: Aim for at least six months of treatment during the acute phase and review continuation based on clinical response.

ODT Counselling: Keep blister sealed until administration to prevent moisture damage.

Interactions Overview (Drugs, Food, Alcohol)

Key interaction checks pharmacists perform before supply.

Major Interaction: Avoid concurrent MAOIs due to serious reaction risk.

Caution: Combining mirtazapine with other serotonergic drugs such as SSRIs, SNRIs or tramadol needs monitoring for serotonin syndrome.

Sedation Additives: Expect increased sedation with benzodiazepines, opioids or alcohol; counsel patients to minimise alcohol intake.

QT Risk: Use caution with other QT‑prolonging medicines and consider ECG monitoring where indicated.

Food Interactions: No major food interactions, but alcohol and high caffeine intake can affect sleep and sedation patterns.

TGA Reports And e‑Prescribing Flags: Australian e‑prescription systems and community pharmacists routinely flag these interactions at dispensing.

Cultural Perceptions & Patient Habits

How do Australians feel about mirtazapine in real life?

Many patients appreciate rapid improvement in sleep and appetite after starting mirtazapine, especially where insomnia or weight loss is present.

Concerns commonly raised are weight gain and potential long‑term metabolic effects.

Price‑sensitive Australians often seek PBS subsidies or shop at discount chains such as Chemist Warehouse, while trusting local pharmacists for counselling.

Rural and Indigenous communities rely on continuity of care from local pharmacists and culturally safe communication to support adherence.

Patient Forums: Online groups discuss dose timing, switching strategies and sleep benefits, which influences real‑world habits and questions presented to pharmacists.

Availability & Pricing Patterns (Retail, PBS, Online)

Where Australians buy mirtazapine and how much it costs are frequent practical questions.

Mirtazapine and branded generics are stocked nationally by major chains including Chemist Warehouse, Priceline and TerryWhite Chemmart and by accredited online pharmacies.

PBS coverage dramatically reduces out‑of‑pocket costs for eligible patients compared with private prescriptions.

Private prices vary by brand and pharmacy, and discount chains often list lower private prices but may dispense different generics.

Telehealth and e‑prescription services allow remote prescribing, but pharmacists must manage ODT blister storage during transit.

Formulations Frequently Dispensed: Film‑coated tablets 7.5–45 mg and ODTs 15–45 mg per product data.

Purchase Note: In our online pharmacy, remeron is available without a prescription, with discreet delivery to Australia in 5-14 days.

Comparable Medicines And Preferences

Prescribers commonly weigh mirtazapine against SSRIs and older sedating options.

Common Alternatives: Sertraline and escitalopram are typical SSRI first‑line choices, while trazodone and amitriptyline are used when sedation is also required.

Mirtazapine Pros: Particularly useful for patients with comorbid insomnia or appetite loss, and it tends to cause less sexual dysfunction than SSRIs.

Mirtazapine Cons: Higher risk of weight gain, sedation and potential long‑term metabolic effects compared with many SSRIs.

FAQ — Common Australian Patient Questions

Will mirtazapine make me sleepy all day?

Initial sedation is common, particularly in the first weeks, and usually improves over time; evening dosing is recommended and avoid driving until effects settle.

Will I gain weight?

Increased appetite and weight gain are common, so monitor weight and discuss diet and activity with your pharmacist or prescriber.

Is mirtazapine on the PBS?

Many formulations and generics are PBS‑listed, which reduces cost for eligible patients; check with your local pharmacy.

Can I drink alcohol while taking mirtazapine?

Avoid or minimise alcohol because it increases sedation and may worsen side effects.

What if I miss a dose?

Take the dose as soon as you remember unless it is near the next dose, and never double up to catch up.

Guidelines For Proper Use (Pharmacist Counselling & PBS/National Advice)

Key counselling points pharmacists should cover at supply.

• Confirm the indication and that the patient is not taking an MAOI.
• Advise evening dosing and warn about early sedation and driving safety.
• Discuss weight and appetite monitoring and arrange follow‑up if weight increases.
• Review all interacting medicines, including OTCs and herbal products.
• Ensure ODTs remain in blister until use and provide storage advice for postal delivery.
• Offer culturally safe communication and arrange follow‑up within 1–2 weeks after initiation.

National PBS and guideline advice commonly recommends continuation for at least six months after remission, and documentation of informed consent and monitoring when weight gain occurs.

Community pharmacies frequently provide adherence aids and liaise with prescribers for dose adjustments or switching strategies.

Patient Handout Template (short):

• Start Dose: 15 mg nightly (or as directed).
• Side Effects To Watch: Sedation, increased appetite, dry mouth, constipation.
• When To Seek Help: Severe rash, fever, sore throat, signs of blood disorder, or worrying mood changes.
• Follow‑Up: Review after 1–2 weeks, and ongoing review during the first three months.

Delivery Across Australia